PIMCO Global StocksPLUS & Income Fund (PGP): Attractive Discount and Robust Yield for Income Investors
Finance

PIMCO Global StocksPLUS & Income Fund (PGP): Attractive Discount and Robust Yield for Income Investors

authorBy Suze Orman
DateJun 14, 2026
Read time2 min

The PIMCO Global StocksPLUS & Income Fund (PGP) currently trades at a discount of 5.31%, making it an attractive option for investors. This valuation is considerably more appealing than its historical average, suggesting a potential upside for new investors. The fund's unique investment strategy combines fixed-income instruments with equity derivatives, offering a hybrid approach that aims to generate consistent income and growth. This blend allows PGP to navigate various market conditions, providing a diversified return stream. Investors looking for a combination of stability from fixed income and potential growth from equity exposure might find PGP particularly interesting at its current discount.

PGP's operational structure employs a multi-sector fixed-income portfolio complemented by strategic equity exposure. This strategy has enabled it to deliver strong relative returns when compared to its sister funds, demonstrating its effectiveness in a complex market. The fund boasts a distribution yield approaching 10%, supported by robust Net Investment Income (NII) coverage and positive Undistributed Net Investment Income (UNII). These financial indicators underscore the sustainability of its distributions, providing confidence to income-seeking investors. The diversified global portfolio and the use of leverage to enhance equity exposure position PGP as a compelling choice for aggressive investors prioritizing income.

PGP’s current discount and high distribution yield, combined with its well-managed hybrid strategy, offer a unique value proposition. This fund stands as a testament to strategic diversification and active management, aiming to provide both capital appreciation and significant income. For investors seeking a balanced yet aggressive approach to income investing, PGP represents a thoughtful and potentially rewarding opportunity in today’s market landscape.

More Articles
Finance
On Holding: The Future of Athleisure Footwear
On Holding AG (ONON) is rapidly emerging as a leading brand in the athletic and leisure apparel market. The company distinguishes itself by offering premium, comfortable, and versatile sneakers suitable for both athletic performance and casual wear. With impressive revenue growth and healthy gross margins, On Holding presents an attractive investment opportunity. Despite potential risks such as fashion trends and management changes, the brand's unique identity and strong founder involvement offer a degree of stability. Its current valuation appears reasonable for a company demonstrating sustained growth and improving profitability.
By Nouriel RoubiniJun 14, 2026
Finance
Adobe's Stock Performance: Challenges and Future Outlook
Despite consistent revenue growth and strong financial results, Adobe's stock has experienced a significant downturn, dropping by 50% over the past year. The market remains skeptical about the company's future in the age of AI, and recent strategic shifts, such as a move towards a freemium model, have further unsettled investors. This report examines Adobe's recent financial performance, its challenges, and potential pathways for a stock rebound.
By Michele FerreroJun 13, 2026
Finance
Ciena Corporation Secures Significant Debt Offering for Strategic Growth and Shareholder Value
Ciena Corporation recently finalized a substantial $2.5 billion convertible senior notes offering, an increase from its initial $2 billion plan. This financial maneuver aims to bolster the company's supply chain capabilities and enhance shareholder returns through share repurchases, debt repayment, and general corporate investments, solidifying its position as a key player in telecommunications networking.
By Lisa JingJun 13, 2026
Finance
Cytokinetics' MYQORZO Launched in Germany for Obstructive HCM
Cytokinetics has initiated the commercial launch of MYQORZO (aficamten) in Germany, targeting symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This follows European Commission approval in February and previous regulatory clearances in the United States and China. MYQORZO, a cardiac myosin inhibitor, demonstrated significant improvements in patient outcomes during its Phase 3 clinical trials, marking a crucial step in the company's European expansion strategy.
By Suze OrmanJun 13, 2026
Finance
Semtech Corporation: A Promising Investment in the Data Center Industry
Semtech Corporation (SMTC) is highlighted as a compelling stock for June, receiving a reiterated 'Buy' rating and an increased price target from UBS. This positive outlook is driven by Semtech's strong first-quarter performance, fueled by robust demand in the 800G optical market and significant growth in its data center and LoRa segments. The company's innovative 'fabless' model, focusing on R&D and IP, positions it for continued expansion, particularly with the anticipated acceleration of 1.6T Optical ecosystem development.
By Morgan HouselJun 13, 2026